6533b824fe1ef96bd1280a7e
RESEARCH PRODUCT
Consensus nomenclature for CD8(+) T cell phenotypes in cancer
Jean-yves BlayGlenn DranoffRoland S. LiblauWillem W. OverwijkMadhav V. DhodapkarPramod K. SrivastavaSjoerd H. Van Der BurgMarc BonnevilleCharles G. DrakeDrew M. PardollDirk JägerJohn M. KirkwoodLisa H. ButterfieldJean Pierre AbastadoWeiping ZouPedro RomeroFederica CavalloMario P. ColomboPawel KalinskiTheresa L. WhitesideSacha GnjaticChiara CastelliBenoît Van Den EyndeIgnacio MeleroFrancesco M. MarincolaG. CoukosAnne CaignardLionel ApetohMichael T. LotzeRon N. ApteDanila ValmoriDanila ValmoriPierre Van Der BruggenEnrico LugliRolf KiesslingEsteban CelisElizabeth A. MittendorfMaha AyyoubEli GilboaGerold SchulerAntoni RibasEric TartourLieping ChenIan H. FrazerMark J. SmythAlexander KnuthRobert D. SchreiberNicholas P. RestifoWolf Hervé FridmanBegoña Comin-anduixGiorgio ParmianiDaniel E. SpeiserAnna Karolina PaluckaKunle OdunDmitry I. GabrilovichEna WangCornelis J. M. MeliefAna C. AndersonHoward L. KaufmanThorsten R. Mempelsubject
senescenceT cellOncology and CarcinogenesisImmunology[SDV.CAN]Life Sciences [q-bio]/CancerBiologyCD8+ T cellsIFN gammaanergy03 medical and health sciencesstemness0302 clinical medicineImmune system[SDV.CAN] Life Sciences [q-bio]/Cancerexhaustionmedicine2.1 Biological and endogenous factorsImmunology and AllergyCytotoxic T cellAetiologyPoint of ViewCancer030304 developmental biologyCD8+ T cells; IFNγ; anergy; anticancer immunity; cytotoxicity; effector; exhaustion; senescence; stemness0303 health sciencesTumor microenvironmentCD8(+) T cellsCancermedicine.diseasePhenotype3. Good healthanticancer immunitymedicine.anatomical_structureeffectorOncologyImmunologycytotoxicityCytokine secretionCD8030215 immunologyIFNγdescription
International audience; Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-01-22 |